ישראל -
עברית -
Ministry of Health
ארקוקסיה 90 מג טבליות
organon pharma israel ltd., israel - etoricoxib - טבליות מצופות פילם - etoricoxib 90 mg - etoricoxib
ישראל -
עברית -
Ministry of Health
רמסימה 120 מגמל תת-עורי
padagis israel agencies ltd, israel - infliximab - תמיסה להזרקה - infliximab 120 mg/ml - infliximab
ישראל -
עברית -
Ministry of Health
טאלץ 80 מג
eli lilly israel ltd, israel - ixekizumab - תמיסה להזרקה - ixekizumab 80 mg / 1 ml - ixekizumab
ישראל -
עברית -
Ministry of Health
סימזיה
neopharm ltd, israel - certolizumab pegol - תמיסה להזרקה - certolizumab pegol 200 mg/ml - certolizumab pegol
ישראל -
עברית -
Ministry of Health
ארלזי 25
novartis israel ltd - etanercept - תמיסה להזרקה - etanercept 25 mg / 0.5 ml - etanercept
ישראל -
עברית -
Ministry of Health
ארלזי 50
novartis israel ltd - etanercept - תמיסה להזרקה - etanercept 50 mg / 1 ml - etanercept
ישראל -
עברית -
Ministry of Health
אידסיו
neopharm (israel)1996 ltd - adalimumab - תמיסה להזרקה - adalimumab 50 mg/ml - adalimumab
ישראל -
עברית -
Ministry of Health
אמג'ויטה
amgen europe b.v. - adalimumab - תמיסה להזרקה - adalimumab 50 mg / 1 ml - adalimumab
ישראל -
עברית -
Ministry of Health
וימובו
astra zeneca israel ltd - esomeprazole as magnesium trihydrate 20 mg; naproxen 500 mg - tablets modified release - naproxen - vimovo is a combination product that contains naproxen and esomeprazole. it is indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing nsaid-associated gastric ulcers.vimovo is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products.
ישראל -
עברית -
Ministry of Health
וימובו
astra zeneca israel ltd - esomeprazole as magnesium trihydrate 20 mg; naproxen 500 mg - tablets modified release - naproxen - vimovo is a combination product that contains naproxen and esomeprazole. it is indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing nsaid-associated gastric ulcers. vimovo is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products.